Holen Sie sich die Stockscreener-App
6.83
1.64%
0.11
Handel nachbörslich:
6.66
-0.17
-2.49%
Schlusskurs vom Vortag:
$6.72
Offen:
$6.8
24-Stunden-Volumen:
851.32K
Relative Volume:
0.73
Marktkapitalisierung:
$366.38M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.4627
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
+8.24%
1M Leistung:
+6.72%
6M Leistung:
-18.88%
1J Leistung:
+4.12%
1-Tages-Spanne:
$6.69
$6.95
1-Wochen-Bereich:
$6.15
$6.98
52-Wochen-Spanne:
$4.02
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
6.83 | 366.38M | 1.02B | -757.20M | -257.90M | -14.76 |
|
RGC
Regencell Bioscience Holdings Ltd
|
20.19 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
155.79 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.42 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.06 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.56 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Government Contract Update: $62M payment to EMERGENT BIOSOLUTIONS CANADA INC - Nasdaq
BRIEF—LigaChem links up with NovaRock - The Pharma Letter
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact Its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO’s Insider Sales - ACCESS Newswire
Emergent BioSolutions at Jefferies Conference: Strategic Transformation By Investing.com - Investing.com Canada
Squarepoint Ops LLC Has $451,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions (EBS) Partners with Foundation for Opioid Awareness | EBS Stock News - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's Nat - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies | EBS Stock News - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies - The Manila Times
Breaking: Dramatic 34% Drop in US Opioid Deaths as Emergent Expands Life-Saving Naloxone Access - Stock Titan
Vaccine Contract Manufacturing Market Set to Witness - openPR.com
Biodefense Market Set to Witness Significant GrowthEmergent BioSolutions Inc., SIGA Technologies - openPR.com
Bank of America Corp DE Boosts Stake in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Investors Can Still File Late Claims in Emergent BioSolutions Settlement - TradingView
Northern Trust Corp Acquires 3,692 Shares of Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions discloses CEO stock purchase - MSN
Emergent Biosolutions Settlement Receives Preliminary Approval - TipRanks
Emergent BioSolutions at RBC Conference: Strategic Turnaround Focus By Investing.com - Investing.com India
Emergent BioSolutions ($EBS) Is Paying a $40M Settlement to Investors — Here’s How to Get Your Share - TradingView
Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions - Yahoo Finance
Q1 EPS Forecast for Emergent BioSolutions Lowered by Analyst - Defense World
Emergent BioSolutions (EBS) Shares Surge 9.7% Following Positive Developments | EBS Stock News - GuruFocus
Emergent BioSolutions (EBS) CEO Increases Stake with $350,000 Sh - GuruFocus
Emergent BioSolutions (EBS) Shares Surge Over 13% | EBS Stock Ne - GuruFocus
Emergent BioSolutions (EBS) Shares Surge Over 14% | EBS Stock Ne - GuruFocus
Emergent BioSolutions (EBS) Shares Surge Over 14% | EBS Stock News - GuruFocus
Emergent BioSolutions (EBS) Shares Surge Over 13% | EBS Stock News - GuruFocus
Emergent BioSolutions stock up on insider purchase (EBS:NYSE) - Seeking Alpha
Insider Buying: Joseph Papa Acquires 60,000 Shares of Emergent B - GuruFocus
Insider Buying: Joseph Papa Acquires 60,000 Shares of Emergent BioSolutions Inc (EBS) - GuruFocus
Emergent BioSolutions to Participate in Upcoming Investor Conferences | EBS Stock News - GuruFocus
Emergent BioSolutions to Participate in Upcoming Investor Conferences - The Manila Times
Emergent BioSolutions Lines Up 4 Major Wall Street Conferences: RBC, Goldman Sachs, Jefferies Featured - Stock Titan
Wells Fargo & Company MN Sells 11,665 Shares of Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions Inc.'s (NYSE:EBS) Share Price Boosted 29% But Its Business Prospects Need A Lift Too - simplywall.st
Emergent BioSolutions (EBS) Q1 2025 Earnings Highlight Turnaroun - GuruFocus
Emergent Biosolutions Q1 2025 Earnings Preview - MSN
Emergent BioSolutions Inc. (NYSE:EBS) Q1 2025 Earnings Call Transcript - Insider Monkey
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates - MSN
Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress - MSN
Emergent Biosolutions: Q1 Earnings Snapshot - New Haven Register
Emergent BioSolutions Inc. SEC 10-Q Report - TradingView
Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ... - Yahoo
Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid Revenue Challenges - GuruFocus
Earnings call transcript: Emergent BioSolutions Q1 2025 sees 656% net income rise - Investing.com Nigeria
Emergent Biosolutions earnings beat by $0.22, revenue fell short of estimates - Investing.com
Emergent Biosolutions Q1 2025 slides: turnaround progress drives profitability By Investing.com - Investing.com India
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.92%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):